FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
|Videos|September 12, 2016
Tim & Meghan: A Survivor’s Journey
Author(s)Melanoma Foundation of New England
Advertisement
Both Tim and Meghan have had first hand experiences with melanoma, the deadliest form of skin cancer. Walk through their journeys with them as they tell their stories.
Advertisement
Related to this article
At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.
For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
KEYNOTE-564 data show adjuvant pembrolizumab maintains DFS and OS benefits in ccRCC. Review key nursing takeaways and safety outcomes.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer
2
Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles
3
Recognizing and Evaluating Diarrhea in Metastatic Triple-Negative Breast Cancer
4
WCLC 2026: Oncology Nursing Takeaways on Supportive Care and APP-Led Models
5